vs

Side-by-side financial comparison of RE/MAX Holdings, Inc. (RMAX) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $71.1M, roughly 1.8× RE/MAX Holdings, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -4.7%).

RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

RMAX vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.8× larger
ZLAB
$127.1M
$71.1M
RMAX
Growing faster (revenue YoY)
ZLAB
ZLAB
+19.0% gap
ZLAB
17.1%
-1.8%
RMAX
More free cash flow
RMAX
RMAX
$60.2M more FCF
RMAX
$33.5M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-4.7%
RMAX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RMAX
RMAX
ZLAB
ZLAB
Revenue
$71.1M
$127.1M
Net Profit
$1.4M
Gross Margin
51.0%
Operating Margin
13.1%
-54.6%
Net Margin
2.0%
Revenue YoY
-1.8%
17.1%
Net Profit YoY
-75.2%
EPS (diluted)
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$71.1M
$127.1M
Q3 25
$73.2M
$115.4M
Q2 25
$72.8M
$109.1M
Q1 25
$74.5M
$105.7M
Q4 24
$72.5M
$108.5M
Q3 24
$78.5M
$101.8M
Q2 24
$78.5M
$100.1M
Q1 24
$78.3M
$87.1M
Net Profit
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$1.4M
Q3 25
$4.0M
$-36.0M
Q2 25
$4.7M
$-40.7M
Q1 25
$-2.0M
$-48.4M
Q4 24
$5.8M
Q3 24
$966.0K
$-41.7M
Q2 24
$3.7M
$-80.3M
Q1 24
$-3.4M
$-53.5M
Gross Margin
RMAX
RMAX
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
RMAX
RMAX
ZLAB
ZLAB
Q4 25
13.1%
-54.6%
Q3 25
25.0%
-42.3%
Q2 25
19.3%
-50.3%
Q1 25
7.2%
-53.3%
Q4 24
5.9%
-62.6%
Q3 24
19.4%
-66.6%
Q2 24
20.6%
-76.0%
Q1 24
5.8%
-80.7%
Net Margin
RMAX
RMAX
ZLAB
ZLAB
Q4 25
2.0%
Q3 25
5.4%
-31.2%
Q2 25
6.4%
-37.3%
Q1 25
-2.6%
-45.8%
Q4 24
8.0%
Q3 24
1.2%
-40.9%
Q2 24
4.7%
-80.2%
Q1 24
-4.3%
-61.4%
EPS (diluted)
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$-0.05
Q3 25
$-0.03
Q2 25
$-0.04
Q1 25
$-0.04
Q4 24
$-0.09
Q3 24
$-0.04
Q2 24
$-0.08
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RMAX
RMAX
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$118.7M
$689.6M
Total DebtLower is stronger
$432.2M
Stockholders' EquityBook value
$452.4M
$715.5M
Total Assets
$582.5M
$1.2B
Debt / EquityLower = less leverage
0.96×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$118.7M
$689.6M
Q3 25
$107.5M
$717.2M
Q2 25
$94.3M
$732.2M
Q1 25
$89.1M
$757.3M
Q4 24
$96.6M
$779.7M
Q3 24
$83.8M
$616.1M
Q2 24
$66.1M
$630.0M
Q1 24
$82.1M
$650.8M
Total Debt
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$432.2M
Q3 25
$433.3M
Q2 25
$434.4M
Q1 25
$435.3M
Q4 24
$436.2M
Q3 24
$437.2M
Q2 24
$438.1M
Q1 24
$439.0M
Stockholders' Equity
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$452.4M
$715.5M
Q3 25
$448.1M
$759.9M
Q2 25
$442.4M
$791.7M
Q1 25
$433.5M
$810.8M
Q4 24
$429.5M
$840.9M
Q3 24
$423.1M
$667.7M
Q2 24
$418.4M
$704.2M
Q1 24
$412.0M
$762.2M
Total Assets
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$582.5M
$1.2B
Q3 25
$582.2M
$1.2B
Q2 25
$574.8M
$1.2B
Q1 25
$571.4M
$1.2B
Q4 24
$581.6M
$1.2B
Q3 24
$578.6M
$985.3M
Q2 24
$571.4M
$987.4M
Q1 24
$566.7M
$988.4M
Debt / Equity
RMAX
RMAX
ZLAB
ZLAB
Q4 25
0.96×
Q3 25
0.97×
Q2 25
0.98×
Q1 25
1.00×
Q4 24
1.02×
Q3 24
1.03×
Q2 24
1.05×
Q1 24
1.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RMAX
RMAX
ZLAB
ZLAB
Operating Cash FlowLast quarter
$40.9M
$-26.0M
Free Cash FlowOCF − Capex
$33.5M
$-26.7M
FCF MarginFCF / Revenue
47.1%
-21.0%
Capex IntensityCapex / Revenue
10.4%
0.5%
Cash ConversionOCF / Net Profit
28.39×
TTM Free Cash FlowTrailing 4 quarters
$56.8M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$40.9M
$-26.0M
Q3 25
$17.7M
$-32.0M
Q2 25
$4.6M
$-31.0M
Q1 25
$5.7M
$-61.7M
Q4 24
$59.7M
$-55.8M
Q3 24
$17.6M
$-26.8M
Q2 24
$15.9M
$-42.2M
Q1 24
$9.4M
$-90.1M
Free Cash Flow
RMAX
RMAX
ZLAB
ZLAB
Q4 25
$33.5M
$-26.7M
Q3 25
$16.4M
$-35.0M
Q2 25
$2.9M
$-33.9M
Q1 25
$4.0M
$-63.2M
Q4 24
$53.0M
$-58.4M
Q3 24
$16.3M
$-28.2M
Q2 24
$14.0M
$-42.9M
Q1 24
$6.8M
$-91.1M
FCF Margin
RMAX
RMAX
ZLAB
ZLAB
Q4 25
47.1%
-21.0%
Q3 25
22.4%
-30.4%
Q2 25
4.0%
-31.1%
Q1 25
5.3%
-59.9%
Q4 24
73.2%
-53.8%
Q3 24
20.8%
-27.7%
Q2 24
17.8%
-42.9%
Q1 24
8.6%
-104.5%
Capex Intensity
RMAX
RMAX
ZLAB
ZLAB
Q4 25
10.4%
0.5%
Q3 25
1.8%
2.6%
Q2 25
2.2%
2.6%
Q1 25
2.3%
1.5%
Q4 24
9.1%
2.4%
Q3 24
1.7%
1.3%
Q2 24
2.4%
0.7%
Q1 24
3.3%
1.1%
Cash Conversion
RMAX
RMAX
ZLAB
ZLAB
Q4 25
28.39×
Q3 25
4.45×
Q2 25
0.97×
Q1 25
Q4 24
10.28×
Q3 24
18.22×
Q2 24
4.29×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RMAX
RMAX

Franchising Segment$50.1M70%
Broker Fees$13.9M20%
Annual Dues$7.4M10%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons